Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Monoclonal antibodies are often linked to alopecia areata cases.

Tofacitinib treatment for hair loss may worsen acne.

Talquetamab may cause hair loss and skin issues.

JAK inhibitors are effective for severe alopecia areata but need better strategies for long-term use and personalized treatment.

RACB in barley is crucial for cell polarity and nucleus positioning, aiding fungal infection.

Avacopan may cause unexpected side effects, so early monitoring is important.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.

Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.

Adalimumab may cause severe hair loss in some patients.

Combining ciclosporin and simvastatin can cause severe kidney damage.

Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.

New oral anticoagulants are safer and easier to use with new reversal agents for bleeding emergencies.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

Some gonadal hormone drugs can block filovirus entry into cells.

Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.

Coinheritance of BRCA2 and CYLD genes may lead to new treatment options for certain cancers.

Beard alopecia areata causes patchy beard hair loss, often treatable with janus kinase inhibitors.

Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.

Upadacitinib effectively treats severe alopecia areata and is safe.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.

New therapies for Birt–Hogg–Dubé syndrome are being developed based on understanding the FLCN gene's role.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.